Professor Alan Trounson (Cartherics)2023-11-17T16:00:37
The suitability of NK cells for cancer therapy has been challenged by some investor and business interests because of limited efficacy data, is this a valid belief at the present stage of development of the immune therapy field?
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-10-07T14:00:00Z
Sponsored by WuXi AppTec
2025-05-28T14:00:00
Sponsored by Eurofins DiscoverX
2023-07-04T09:00:08
Sponsored by SB Drug Discovery
2024-02-01T11:52:50
Sponsored by Leica Microsystems
2023-01-05T14:41:33
Sponsored by Cell Signaling Technology
Site powered by Webvision Cloud